CurrentNeighborhood Health Plan of Rhode IslandPolicy 2901-A

Vemlidy (tenofovir alafenamide) coverage for hepatitis B

Policy governs authorization criteria for Vemlidy (tenofovir alafenamide) for treatment of chronic hepatitis B, HBV/HIV coinfection, and HBV reactivation/reinfection prophylaxis for members of Neighborhood Health Plan of Rhode Island.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyVemlidy (tenofovir alafenamide) coverage for hepatitis B

Policy CodePolicy 2901-A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain prior authorization and document compensated liver disease, HIV-1 status, and antiretroviral regimen components when applicable.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthsinitial auth duration (chronic HBV / HBV/HIV)

12 monthsinitial auth duration (reactivation prophylaxis)

12 monthsreauthorization duration

>=12 yrsminimum age (FDA)

Coverage Criteria for Vemlidy (tenofovir alafenamide)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy - Chronic HBV